Women with advanced uterine / endometrial cancer are usually treated with chemotherapy.
Those who failed chemotherapy or those who are fit for chemotherapy are sometimes treated with hormone treatment.
Letrozole is one such hormone treatment for those patients with hormone sensitive cancer.
The trial data presented at the ESMO ( European Society of Medical Oncology) is very promising.
If large trials confirm this finding, the combination would be standard treatment in future.
Disclaimer: Please note- This blog is NOT medical advice. This blog is purely for information only and do check the the sources where cited. Please consult your own doctor to discuss concerns and options relevant to you.
The views expressed in this blog represent the author’s views held at the time of drafting the blog and is likely to change overtime, particularly when new evidence comes to light. The blog is not necessarily endorsed by any organisation the author is associated with and views are not substitute for professional advice.